v3.20.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Revenue:        
Contract research revenue $ 95,833 $ 95,833 $ 89,812
Costs and expenses:        
Research and development 3,336,225 2,671,365 10,833,345 7,814,842
General and administrative 2,364,214 1,889,892 6,980,155 5,460,023
Total costs and expenses 5,700,439 4,561,257 17,813,500 13,274,865
Loss from operations (5,604,606) (4,561,257) (17,717,667) (13,185,053)
Sale of New Jersey net operating loss 1,073,289 1,007,082
Other income, net 155,093 156,872 538,420 378,151
Net loss (5,449,513) (4,404,385) (16,105,958) (11,799,820)
Preferred stock series A accumulated dividends (45,041) (338,613)
Preferred stock series B accumulated dividends (227,600) (115,500) (575,392) (349,500)
Net loss attributable to common shareholders $ (5,677,113) $ (4,564,926) $ (16,681,350) $ (12,487,933)
Net loss available for common shareholders per share - basic and diluted $ (0.03) $ (0.03) $ (0.09) $ (0.09)
Weighted average common shares outstanding - basic and diluted 198,909,016 156,889,602 196,070,952 139,265,178
Other comprehensive (loss)/income, net of tax        
Net unrealized (loss)/gain on securities available-for-sale $ (114,159) $ 367,144
Reclassifications to net loss (2,719)
Other comprehensive (loss)/income, net of tax (114,159) 364,425
Comprehensive loss attributable to shareholders $ (5,563,672) $ (4,404,385) $ (15,741,533) $ (11,799,820)

Source